COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D07YLV
|
|||
Drug Name |
Ciclesonide
|
|||
Synonyms |
Ciclesonide; Omnaris; Alvesco; Zetonna; 126544-47-6; RPR 251526; RPR251526; UNII-S59502J185; RPR-251526; Ciclesonide [INN]; S59502J185; 141845-82-1; Osonide; Osonase; Omnair; Omnaris HFA; Alvesco HFA; Ciclesonide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 3 | [1] | |
Other Indication | Asthma | Approved | [2] | |
Therapeutic Class |
Antiviral Agents
|
|||
Structure |
Download2D MOL |
|||
Formula |
C32H44O7
|
|||
Canonical SMILES |
CC(C)C(=O)OCC(=O)C12C(CC3C1(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)OC(O2)C6CCCCC6
|
|||
InChI |
1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1
|
|||
InChIKey |
LUKZNWIVRBCLON-GXOBDPJESA-N
|
|||
CAS Number |
CAS 126544-47-6
|
|||
PubChem Compound ID | ||||
ChEBI ID |
CHEBI:31397
|
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT04377711) A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients. U.S. National Institutes of Health. | |||
2 | FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 202129 |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.